0001626199-23-000119.txt : 20231108
0001626199-23-000119.hdr.sgml : 20231108
20231108172054
ACCESSION NUMBER: 0001626199-23-000119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231106
FILED AS OF DATE: 20231108
DATE AS OF CHANGE: 20231108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rickey James Paul
CENTRAL INDEX KEY: 0001606243
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 231389302
MAIL ADDRESS:
STREET 1: ALPINE IMMUNE SCIENCES, INC.
STREET 2: 188 EAST BLAINE STREET, SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
wk-form4_1699482039.xml
FORM 4
X0508
4
2023-11-06
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001606243
Rickey James Paul
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
0
1
0
0
See Remarks
1
Common Stock
2023-11-06
4
M
0
10989
3.23
A
18003
D
Common Stock
2023-11-06
4
S
0
18003
16.0281
D
0
D
Stock Option (Right to buy)
3.23
2023-11-06
4
M
0
10989
0
D
2030-01-22
Common Stock
10989
91011
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023.
This transaction was executed in multiple trades at prices ranging from $16.00 to $16.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date.
/s/ James Paul Rickey
2023-11-08